Polydipsia and dopamine: behavioral effects of dopamine D1 and D2 receptor agonists and antagonists. 1994

G Mittleman, and A L Rosner, and C L Schaub
Department of Psychology, Memphis State University, Tennessee.

Substantial evidence implicates dopaminergic neural systems in the occurrence of polydipsia in both animals and humans. Two experiments were conducted in order to specify the behavioral mechanisms whereby manipulation of dopaminergic neural transmission can affect scheduled-induced polydipsia (SIP). The role of dopamine D1 and D2 receptors was investigated by comparing the behavioral effects of dopamine D1 agonists (SKF 38393 and SKF 82958) and antagonists (SCH 23390 and SKF 83566) to those of a dopamine D2 agonist (quinpirole) and antagonist (haloperidol) by using an animal model of excessive water consumption, drinking evoked in the SIP paradigm. Additionally, the behavioral effects of these relatively specific compounds were compared to those of the indirect agonist d-amphetamine sulfate and the nondopaminergic drug, diazepam. All of the drugs produced dose-related decreases in SIP. With the exception of SKF 38393 and SCH 23390, the decreased drinking appeared to be a behaviorally nonspecific drug effect in that changes in activity consistently preceded or accompanied reductions in water consumption. Some of the drugs tested, including quinpirole, haloperidol and SKF 83566, also produced changes in behavior consistent with decreased hunger, which may have also contributed to the reductions in SIP. These results are generally suggestive that dopamine neural systems are involved mainly in the motor or performance aspects of established SIP and that disruptions in established SIP produced by dopamine agonists or antagonists may result from a change in the balance of activation of dopamine D1 and D2 receptors. These results may be relevant to understanding the factors influencing polydipsia in humans.

UI MeSH Term Description Entries
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D003975 Diazepam A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity. 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one,Apaurin,Diazemuls,Faustan,Relanium,Seduxen,Sibazon,Stesolid,Valium
D004326 Drinking The consumption of liquids. Water Consumption,Water Intake,Drinkings
D004435 Eating The consumption of edible substances. Dietary Intake,Feed Intake,Food Intake,Macronutrient Intake,Micronutrient Intake,Nutrient Intake,Nutritional Intake,Ingestion,Dietary Intakes,Feed Intakes,Intake, Dietary,Intake, Feed,Intake, Food,Intake, Macronutrient,Intake, Micronutrient,Intake, Nutrient,Intake, Nutritional,Macronutrient Intakes,Micronutrient Intakes,Nutrient Intakes,Nutritional Intakes
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001552 Benzazepines Compounds with BENZENE fused to AZEPINES.
D013894 Thirst A drive stemming from a physiological need for WATER. Thirsts

Related Publications

G Mittleman, and A L Rosner, and C L Schaub
January 1988, Advances in experimental medicine and biology,
G Mittleman, and A L Rosner, and C L Schaub
September 1991, The Journal of pharmacology and experimental therapeutics,
G Mittleman, and A L Rosner, and C L Schaub
December 1990, European journal of pharmacology,
G Mittleman, and A L Rosner, and C L Schaub
October 2003, Sheng li xue bao : [Acta physiologica Sinica],
G Mittleman, and A L Rosner, and C L Schaub
July 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience,
G Mittleman, and A L Rosner, and C L Schaub
January 1989, Psychopharmacology series,
G Mittleman, and A L Rosner, and C L Schaub
October 1991, Journal of cardiovascular pharmacology,
G Mittleman, and A L Rosner, and C L Schaub
January 1993, Pharmacology & toxicology,
G Mittleman, and A L Rosner, and C L Schaub
May 1990, Behavioural brain research,
Copied contents to your clipboard!